[1]张士保,朱斐煜,谢瑞玉,等.CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究[J].现代检验医学杂志,2022,37(05):44-49.[doi:10.3969/j.issn.1671-7414.2022.05.010]
　ZHANG Shi-bao,ZHU Fei-yu,XIE Rui-yu,et al.Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis[J].Journal of Modern Laboratory Medicine,2022,37(05):44-49.[doi:10.3969/j.issn.1671-7414.2022.05.010]
点击复制

CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年05期
页码:
44-49
栏目:
论著
出版日期:
2022-09-15

文章信息/Info

Title:
Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis
文章编号:
1671-7414（2022）05-044-06
作者:
张士保1; 朱斐煜1; 谢瑞玉2; 尚宪平2
1. 来安家宁医院检验科，安徽滁州 239200；2. 滁州市第一人民医院检验科，安徽滁州 239200
Author(s):
ZHANG Shi-bao1;  ZHU Fei-yu1;  XIE Rui-yu2;  SHANG Xian-ping2
1.Department of Clinical Laboratory, Laianjianing Hospital, Anhui Chuzhou 239200, China;2.Department of Clinical Laboratory, Chuzhou First People’s Hospital, Anhui Chuzhou 239200, China
关键词:
前列腺癌; 环状核糖核酸-100395; 甲基化状态; miRNA-136-5p/Smad3; 细胞增殖; 细胞侵袭
分类号:
R373.19；R446
DOI:
10.3969/j.issn.1671-7414.2022.05.010
文献标志码:
A
摘要:
目的　检测前列腺癌细胞中环状核糖核酸（circular RNAs, CircRNA）100395 基因启动子区甲基化状态及其表达水平，研究CircRNA-100395 基因去甲基化对前列腺癌细胞增殖、侵袭的影响及作用机制。方法　选择人正常前列腺上皮细胞（RWPE）和前列腺癌细胞系（LNCap，PC3 和DU145）进行研究。采用甲基化特异性聚合酶链式反应(methylationspecific polymerase chain reaction, MSP) 检测CircRNA-100395 基因启动子区甲基化状态。采用实时荧光定量聚合酶链反应(qRT-PCR) 法检测上述细胞中CircRNA-100395 mRNA 表达水平。应用去甲基药物5- 氮杂-2'- 脱氧胞苷（AZA）处理LNCap 细胞，检测AZA 去甲基化处理前后细胞中CircRNA-100395 表达水平。采用CCK-8 和Transwell 实验检测CircRNA-100395 基因去甲基化前后LNCap 细胞增殖和侵袭能力。构建CircRNA-100395 野生型和突变型质粒，通过双荧光素酶报告分析CircRNA-10039 与miRNA-136-5p 之间的靶向关系；利用qRT-PCR 检测CircRNA-10039 与miRNA-136-5p 表达水平，验证其调控关系。采用Westernblot 法检测AZA 去甲基化和miRNA-136-5p 过表达对Smad3，p-Smad3 蛋白表达的影响。结果　前列腺癌细胞中CircRNA-100395 呈高甲基化状态；LNCap，PC3 及DU145 细胞中CircRNA-100395 相对表达水平分别为0.39±0.08，0.65±0.14，0.62±0.10，显著低于RWPE（1.12±0.15）细胞中表达水平，差异有统计学意义（F=42.076，P ＜ 0.001）。经AZA 去甲基化处理后，LNCap 细胞中CircRNA-100395 表达水平为1.02±0.17，较未处理LNCap 细胞（0.42±0.05）明显升高，差异有统计学意义（t=5.808，P ＜ 0.01）。AZA 去甲基化处理显著抑制了LNCap 细胞的增殖能力（t=8.764~12.970，均P ＜ 0.001）、迁移能力（t=6.092，P ＜ 0.01）。miRNA-136-5 可能是CircRNA-100395 的下游靶基因。未经AZA 处理前LNCap 细胞中CircRNA-100395，miRNA-136-5p 表达水平分别为0.39±0.08，0.87±0.15，AZA 处理后两者表达水平分别为1.02±0.17，0.35±0.08，差异有统计学意义（t=5.808，5.298，均P ＜ 0.01）。AZA 处理后Smad3 和p-Smad3 蛋白表达明显升高，差异有统计学意义（t=7.394，11.889，均P ＜ 0.01）；miRNA-136-5p 过表达抑制了Smad3 和p-Smad3 蛋白表达，差异有统计学意义（t=4.996，5.422，均P ＜ 0.01）。结论　CircRNA-100395 基因启动子区的高甲基化状态可以抑制CircRNA-100395 在前列腺癌细胞中的表达水平，去甲基化处理后CircRNA-100395 表达恢复，并抑制前列腺癌细胞增殖和侵袭，其作用机制可能与CircRNA-100395 靶向调控miRNA-136-5p/Smad3 轴有关。
Abstract:
Objective　To investigate the relationship between the methylation status and expression level of CircRNA-100395 gene promoter in prostate cancer cells, and explore the effect and mechanism of CircRNA-100395 demethylation on prostate cancer cell proliferation and invasion. Methods　Human normal prostate epithelial cells (RWPE) and prostate cancer cell lines (LNCaP, PC3 and DU145) were selected for the study. The methylation status of the promoter region of CircRNA-100395 gene was detected by methylation-specific polymerase chain reaction (MSP). The mRNA expression level of CircRNA-100395 was detected by qRT-PCR .LNCaP cells were treated with 5-Aza-2’- deoxycytidine (AZA), a demethylating drug, and the expression level of CircRNA-100395 in cells before and after AZA demethylation was detected. CCK-8 and Transwell experiments were used to detect the proliferation and invasion of LNCaP cells before and after demethylation of CircRNA-100395 gene.The wildtype and mutant plasmids of circRNA-100395 were constructed, the targeting relationship between CircRNA-10039 and miRNA- 136-5p was analyzed by dual-luciferase reporter, and qRT-PCR was used to further confirm the relationship between CircRNA-10039 and miRNA-136-5p.The effects of AZA demethylation and miRNA-136-5p overexpression on the expression of Smad3 and p-smad3 proteins were detected by Western blot. Results　CircRNA-100395 was hypermethylated in prostate cancer cells, the difference was statistically significant. The relative expression levels of CircRNA-100395 in LNCaP, PC3 and DU145 cells were 0.39±0.08, 0.65±0.14 and 0.62±0.10, respectively, which were significantly lower than those in rwpe (1.12±0.15) cells，the difference was statistically significant (F=42.076，P<0.001).After AZA demethylation, the expression level of CircRNA-100395 in LNCaP cells was (1.02±0.17), which was significantly higher than that in untreated LNCaP cells (0.42±0.05), the difference was statistically significant(t=5.808, P<0.01).AZA demethylation significantly inhibited the proliferation (t=8.764~12.970, all P<0.001) and migration (t=6.092, P<0.01) of LNCaP cells.MiRNA-136-5 may be the downstream target gene of CircRNA-100395.The expression levels of CircRNA-100395 and miRNA-136-5p in LNCaP cells before AZA treatment were 0.39±0.08 and 0.87±0.15, respectively. After AZA treatment, the expression levels of the two were 1.02±0.17 and 0.35±0.08, respectively, with statistical significance (t=5.808, 5.298, all P<0.01).The expression of Smad3 and p-smad3 protein increased significantly after aza treatment (t=7.394, 11.889, all P<0.01). The overexpression of miRNA-136-5p inhibited the expression of Smad3 and p-smad3 proteins, and the difference was statistically significant (t=4.996, 5.422, all P<0.01). Conclusion　The abnormal hypermethylation state of the promoter region of CircRNA-100395 gene could inhibit the expression level of CircRNA-100395 in prostate cancer cells. After demethylation, it could restore the expression of CircRNA-100395 and inhibit the proliferation and invasion of prostate cancer cells. The mechanism may be related to the targeted regulation of miRNA-136-5p/Smad3 axis by circRNA-100395.

参考文献/References:

[1] PERNAR C H, EBOT E M, WILSON K M, et al. The epidemiology of prostate cancer[J]. Cold Spring Harbor Perspectives in Medicine, 2018, 8(12): Q030361.
[2] 中国抗癌协会泌尿男生殖系肿瘤专业委员会, 中国临床肿瘤学会前列腺癌专家委员会. 中国前列腺癌患者基因检测专家共识(2020 年版)[J]. 中国癌症杂志, 2020, 30(7): 551-560.
Chinese Anti-Cancer Association Genitourinary Cancer Committee, Chinese Society of Clinical Oncology Committee on Prostate Cancer. Chinese expert consensus on genomic testing of prostate cancer patients (the 2020 edition) [J]. China Oncology, 2020,30(7): 551-560.
[3] MCNEVIN C S, BAIRD A M, MCDERMOTT R, et al. Diagnostic strategies for treatment selection in advanced prostate cancer[J]. Diagnostics(Basel, Switzerland),2021, 11(2):345-352.
[4] SINHA T, PANIGRAHI C, DAS D, et al. Circular RNA translation, a path to hidden proteome[J]. Wiley Interdisciplinary Reviews: RNA, 2022, 13(1): e1685.
[5] HE Haitian, LI Jianhua, LUO Mayao, et al. Inhibitory role of circRNA_100395 in the proliferation and metastasis of prostate cancer cells[J]. J Int Med Res,2021, 49(2): 300060521992215.
[6] YU X P, LIU C G, QIU F, et al. CircRNA-100395 protects breast carcinoma deterioration by targeting MAPK6[J]. Eur Rev Med Pharmacol Sci, 2020, 24(23):12216-12223.
[7] 王兵兵, 杨爽. 环状RNA-100395 对甲状腺乳头状癌潜在的诊断和治疗价值[J]. 中国实验诊断学, 2021,25(3): 438-440.
WANG Bingbing, YANG Shuang. Potential diagnostic and therapeutic value of circular RNA-100395 in papillary thyroid carcinoma[J]. Chinese Journal of Laboratory Diagnosis, 2021, 25(3): 438-440.
[8] LI Xian, LIN Shuihua, MO Zhifeng, et al. CircRNA_ 100395 inhibits cell proliferation and metastasis in ovarian cancer via regulating miR-1228/p53/epithelial-mesenchymal transition (EMT) axis[J]. Journal of Cancer, 2020, 11(3): 599-609.
[9] 张振, 潘晴, 刘旭, 等. circRNA 与肿瘤发生的研究进展[J]. 现代检验医学杂志, 2018, 33(2): 157-159,164.
ZHANG Zhen, PAN Qing, LIU Xu, et al. Research progress of the relationship between circularRNA and tumorigenesis[J]. Journal of Modern Laboratory Medicine, 2018, 33(2): 157-159, 164.
[10] LI Zhe, RUAN Yao, ZHANG Haiyan, et al. Tumorsuppressive circular RNAs: Mechanisms underlying their suppression of tumor occurrence and use as therapeutic targets[J]. Cancer Science, 2019, 110(12):3630-3638.
[11] CHEN Daishi, MA Wei, KE Zhaoyang, et al. CircRNA hsa_circ_100395 regulates miR- 1228/TCF21 pathway to inhibit lung cancer progression[J]. Cell Cycle, 2018,17(16): 2080-2090.
[12] CHENG Zhiyi, LIU Guiyuan, HUANG Chuanjiang,et al. Upregulation of circRNA_100395 sponges miR-142-3p to inhibit gastric cancer progression by targeting the PI3K/AKT axis[J]. Oncology Letters, 2021, 21(5):419.
[13] CHEN Qiaming, CHEN Zhian, CAO Sai, et al. Role of CircRNAs_100395 in proliferation and metastases of liver cancer[J]. Medical Science Monitor, 2019, 25:6181-6192.
[14] POCZTA M, NOWAK E, BIEG D, et al. Epigenetic modifications and gene expression in cancerogenesis[J].Annales Academiae Medicae Silesiensis, 2018, 72: 80-89.
[15] QUAN Yuan, LIANG Fengji, DENG Simin, et al.Mining the selective remodeling of DNA methylation in promoter regions to identify robust gene-level associations with phenotype[J]. Frontiers in Molecular Biosciences, 2021, 8: 597513.
[16] 张雪梅, 田浩, 魏微微, 等. 食管癌组织中miRNA-375 表达及其甲基化与肿瘤发生发展的关系[J]. 山东医药, 2019, 59(1): 9-12.
ZHANG Xuemei, TIAN Hao, WEI Weiwei, et al. Relationships of miRNA-375 expression and its methylation with tumorigenesis in esophageal carcinoma[J]. Shandong Medical Journal, 2019, 59(1):9-12.
[17] EBRAHIMI V, SOLEIMANIAN A，EBRAHIMI T, et al. Epigenetic modifications in gastric cancer: Focus on DNA methylation[J]. Gene, 2020, 742:144577.
[18] JEZIORSKA D M, MURRAY R J S, DE GOBBI M, et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease[J]. Proc Natl Acad Sci USA, 2017, 114(36):E7526-E7535.
[19] LENG Xiaoling, HUANG Guofu, DING Jianbing, et al. Circ_0000043 promotes proliferation, migration,invasiveness and epithelial-mesenchymal transition in breast cancer cell via the miR-136/Smad3 axis[J].Biochem Cell Biol, 2021,99(3):277-285.
[20] KANG Weiting, WANG Qiang, DAI Yun, et al.Hypomethylation of PlncRNA-1 promoter enhances bladder cancer progression through the miR-136-5p/Smad3 axis[J]. Cell Death Dis, 2020, 11(12): 1038.

相似文献/References:

[1]廖洪利,米叶赛尔·阿不都拉.粘着斑激酶在前列腺癌中表达的研究[J].现代检验医学杂志,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
　LIAO Hong-li,MIYESAIER·Abdula.Research on Expression of FAK in Prostate Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
[2]范维肖,刁艳君,马越云,等.超速离心法与QIAGEN膜亲和柱法提取前列腺癌细胞培养上清外泌体的方法学比较[J].现代检验医学杂志,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
　FAN Wei-xiao,DIAO Yan-jun,MA Yue-yun,et al.Comparison of Ultracentrifugation and Membrane Based-Affinity ColumnMethods in Exosome Isolation from Supernatants of Prostate Cancer Cells[J].Journal of Modern Laboratory Medicine,2019,34(05):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
[3]潘良明,沈菲菲,马晓英,等.血清前列腺健康指数对 tPSA灰区前列腺癌患者的诊断价值探讨[J].现代检验医学杂志,2021,36(01):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
　PAN Liang-ming,SHEN Fei-fei,MA Xiao-ying,et al.Diagnostic Value of Serum Prostate Health Index in Prostate Cancer Patients with PSA Gray Area[J].Journal of Modern Laboratory Medicine,2021,36(05):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
[4]何　跃,梁　晶,文礼红,等.前列腺癌患者血清IL-17和IL-35水平表达与临床病理特征以及预后的关系研究[J].现代检验医学杂志,2021,36(04):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
　HE Yue,LIANG Jing,WEN Li-hong,et al.Study on the Relationship between Serum IL-17, IL-35 Levels andClinicopathological Features and Prognosis in Patients with Prostate Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
[5]荣　蓉a,古　颖a,高　翔a,等.前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究[J].现代检验医学杂志,2021,36(06):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
　RONG Rong,GU Ying,GAO Xiang,et al.Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(05):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
[6]阴铭迪,李 林.前列腺癌实验室诊断的最新进展[J].现代检验医学杂志,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
　YIN Ming-di,LI Lin.Recent Advances in Laboratory Diagnosis of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2022,37(05):194.[doi:10.3969/j.issn.1671-7414.2022.05.039]
[7]郑江婷,寸淑娥,尹 冶,等.长链非编码RNA 在前列腺癌治疗抵抗中作用机制的研究进展[J].现代检验医学杂志,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
　ZHENG Jiang-ting,CUN Shu-e,YIN Ye,et al.Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2023,38(05):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
[8]孙 飞,黎春明.基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J].现代检验医学杂志,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
　SUN Fei,LI Chun-ming.Prediction of Immunotherapy Effect and Prognosis of Prostate Cancer Based on Immune Cell Tissue Infiltration Immune Score Model[J].Journal of Modern Laboratory Medicine,2023,38(05):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
[9]姚俊波,贾 波,刘加元,等.前列腺癌患者血清TWEAK 和SREBP-1 水平表达与临床病理特征及无进展生存预后的关系研究[J].现代检验医学杂志,2024,39(03):136.[doi:10.3969/j.issn.1671-7414.2024.05.023]
　YAO Junbo,JIA Bo,LIU Jiayuan,et al.Study on the Serum TWEAK and SREBP-1 Levels in Patients with Prostate Cancer and Their Relationship with Clinical Pathological Characteristics and Progression Free Survival Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(05):136.[doi:10.3969/j.issn.1671-7414.2024.05.023]
[10]张 珑,李月峰,吴 涛,等.前列腺癌患者血清miR-138-5p，miR-212-5p 水平表达及与临床预后价值[J].现代检验医学杂志,2024,39(05):30.[doi:10.3969/j.issn.1671-7414.2024.05.006]
　ZHANG Long,LI Yuefeng,WU Tao,et al.Expression of Serum miR-138-5p and miR-212-5p Levels and Clinical Prognosis Value in Prostate Cancer[J].Journal of Modern Laboratory Medicine,2024,39(05):30.[doi:10.3969/j.issn.1671-7414.2024.05.006]

备注/Memo

备注/Memo:
基金项目：安徽省科技厅重点研究与开发计划项目（201904d07020005）。
作者简介：张士保(1971-)，男，大专，主管检验技师，研究方向：微生物检验，基础分子生物学实验，E-mail：ttrb68625@yeah.net。
通讯作者：谢瑞玉（1965-），男，本科，主任技师，研究方向：临床免疫学，E-mail：cz2ylab@163.com。
更新日期/Last Update: 2022-09-15